Who
Tim Kutzkey
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Surrozen; 10% owner, Eikon Therapeutics; 10% owner, Ngm Biopharmaceuticals; 10% owner, RAPT Therapeutics.
In numbers
- Trades disclosed
- 96
- Buys
- 34
- Sells
- 1
- Bought
- $21.5M
- Sold
- $12.3M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 19 Jun 2019
- Last trade
- 20 Oct 2026
- Last filed
- 22 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Oct 2026filed 22 Oct 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Code X | $5.6M485,830 at $11.60 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Code X | $6.4M548,653 at $11.60 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Code X | $6.0M517,241 at $11.60 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code X | —728,745 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code X | —822,980 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code X | —775,861 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code X | —242,915 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code X | —274,327 | filing |
| 20 Oct 2026filed 22 Oct 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code X | —258,620 | filing |
| 3 Sep 2026filed 8 Sep 2026 | EIKN Eikon TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.0M89,200 at $11.56 | filing |
| 13 May 2026filed 19 May 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,550 at $0.00 | filing |
| 13 May 2026filed 19 May 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,550 at $0.00 | filing |
| 20 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $166K8,484 at $19.60 | filing |
| 20 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $188K9,568 at $19.60 | filing |
| 20 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $166K8,484 at $19.60 | filing |
| 20 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $188K9,568 at $19.60 | filing |
| 16 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $24K1,204 at $20.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $27K1,358 at $20.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $24K1,204 at $20.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | SRZN SurrozenBiotechnology | SEC FORM 4 Bought | $27K1,358 at $20.00 | filing |
News
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressEIKN · manilatimes.net · 19 Oct 2026Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate CancerEIKN · manilatimes.net · 15 Oct 2026Head to Head Review: Surrozen (NASDAQ:SRZN) vs. AbCellera Biologics (NASDAQ:ABCL)SRZN · tickerreport.com · 14 Oct 2026Surrozen Sees Unusually Large Options Volume (NASDAQ:SRZN)SRZN · themarketsdaily.com · 12 Oct 2026Head to Head Analysis: Whitehawk Therapeutics (NASDAQ:WHWK) vs. Surrozen (NASDAQ:SRZN)SRZN · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Tim Kutzkey; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.